10 results about "Viral glycoprotein" patented technology

The present disclosure provides virus-like particles (VLPs) comprising: i) a CRISPR-Cas effector polypeptide; ii) a recombinant lentivirus comprising a nucleotide sequence encoding a therapeutic polypeptide having a length of from about 250 amino acids to about 3,000 amino acids, where the VLP comprises a pseudotyping viral glycoprotein and / or a polypeptide that provides for binding to a target cell. The present disclosure provides systems for producing a VLP. The present disclosure provides methods of delivering a therapeutic protein, using a VLP of the present disclosure.

The present invention relates to synthetic designs or chimeric proteins for pseudotyping baculovirus (Autographa californica nuclear polyhedrosis virus) with the rabies virus glycoprotein G (gG) on its surface (Bac::gG-FL), which can be used in rabies vaccine formulations. The chimeric protein is designed from a gene cassette containing genetic fragments from the ectodomain of the Pasteur variant rabies virus glycoprotein G, a 7-amino-acid connector sequence (GGGGSGG), as well as transmembrane (TM) and cytoplasmic (CT) regions of the baculoviral protein gp64, the arrangement of which in the designed gene cassette is shown in Figure 1.

Disclosed herein are antibodies or antigen binding fragments thereof that specifically bind human CD8. Also disclosed are fusion proteins comprising a Henipavirus glycoprotein G and CD8 antibodies for targeting and transducing cells expressing CD8. Viral vectors and other compositions containing the fusion proteins, as well as methods of using the fusion proteins, are also disclosed.

Provided herein, among other things, are novel and improved glycoproteins, including modified glycoproteins; engineered viral particles comprising such novel and modified glycoproteins; and methods for targeted delivery, for example, to immune cells such as T cells. In some aspects, the engineered viral particles allow targeted delivery of the cargo for various applications, including treating various conditions such as autoimmune diseases and cancer. In some aspects, the engineered viral particles comprise a viral fusogen that is a glycoprotein of Chandipura, Perinet, Piry, Jurona viruses, or variants thereof. In other aspects, the engineered viral particles comprise a modified vesiculovirus glycoprotein mutant, for example, with mutations at amino acids corresponding to positions I347 or R354 of Vesicular Stomatitis Virus G (VSV-G) that reduce binding to Low Density Lipoprotein Receptor (LDL-R).

This application discloses a human monoclonal antibody against Hennipa virus and its preparation and application as a bispecific antibody. By screening memory B cells in fully human antibody-transgenic mice that specifically bind to Nipah virus glycoproteins (G and F proteins), human monoclonal antibodies 14B8 (targeting the F protein) and 4B8 (targeting the G protein) were obtained. Simultaneously, a bispecific antibody 14B8-IgG-4B8-scFv was constructed based on the above antibodies, which is formed by fusing the full antibody (IgG) of 14B8 with a single-chain antibody fragment of 4B8. Experiments demonstrated that the above antibodies exhibit extremely high binding affinity and neutralizing activity against NiV and HeV, and provide excellent in vivo protective efficacy in the LVG Golden Hamster model.

Provided herein are particles comprising a fusion molecule comprising an adhesion molecule linked to a costimulatory molecule or an activation molecule, as well as vectors, such as lentiviral vectors, comprising the same, cells comprising the same, and methods of using the same. The particle may be a lentiviral particle that displays on the surface of the particle a fusion molecule comprising: a) a CD58 extracellular domain, or a functional fragment thereof, b) an antigen-binding fragment of an anti-CD3 antibody, and c) a CD80 or CD86 extracellular domain, or a functional fragment thereof, and a viral glycoprotein (G protein).

The application discloses a preparation method of rabies virus glycoprotein and application thereof, and belongs to the technical field of biological medicines, and comprises the following steps: expressing a glycoprotein G gene of rabies virus containing an extramembrane region, a transmembrane region and an intramembrane region in yeast; performing cell disruption on the yeast, adding a detergent, and obtaining a solution containing rabies virus glycoprotein G; purifying the solution to obtain full-length rabies virus glycoprotein G; and immunizing the prepared full-length rabies virus glycoprotein G through intramuscular injection, oral administration or atomization inhalation. The scheme provided by the application has the advantages of strong immunogenicity, high safety, low production cost and easiness in scaling, solves the problems of complex traditional vaccine process and high cost, and provides a reliable new type of subunit vaccine solution for rabies prevention.

There is provided a viral glycoprotein comprising a glycoprotein comprising one or more mutations at the intracellular domain of the glycoprotein and / or a modified N-terminal that allows the glycoprotein to be resistant towards detect and / or degradation. The mutations may include lysine to arginine mutations at residues 491, 493, 496, 497 and 511 of the VSV glycoprotein. Also disclosed in a polynucleotide, a vector, a host cell, a composition, a method of treating a disease, and use of the glycoprotein in the manufacture of a medicament for treating a disease.

The application discloses an engineered intracellular antibody, which is fused by a Nef protein sequence of HIV-1 and an intracellular antibody sequence for targeting and degrading mutant huntingtin protein, and has simple structure and is easy to artificially synthesize. The application further discloses an exosome carrying the intracellular antibody, wherein a rabies virus glycoprotein peptide segment RVG is expressed on the membrane of the exosome, so that the exosome can specifically target nerve cells, and has high stability, low immunogenicity, and high penetration, and can be injected intravenously and cut to target and efficiently remove the existing mutant huntingtin protein and its aggregates in the brain of a patient, solve the off-target problem of gene therapy, and have important significance for removing the existing mutant huntingtin protein and its aggregates in the brain of a patient with late Huntington's disease.